Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.

Arteriosclerosis, thrombosis, and vascular biology - 1 Mar 2017

Tardif Jean-Claude, Rhainds David, Rhéaume Eric, Dubé Marie-Pierre

Abstract excerpt

High-density lipoproteins are involved in reverse cholesterol transport and possess anti-inflammatory and antioxidative properties. Paradoxically, CETP (cholesteryl ester transfer protein) inhibitors have been shown to increase inflammation as revealed by a raised plasma level of high-sensitivity C-reactive protein. CETP inhibitors did not improve clinical outcomes in large-scale clinical trials of unselected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenylyl Cyclases
Share to Amides
Share to Anticholesteremic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol Ester Transfer Proteins

Share to Dyslipidemias

Share to Esters

Share to Pharmacogenomic Variants

Share to Sulfhydryl Compounds

Source

Identifiers

PMID: 28126828
DOI: 10.1161/ATVBAHA.116.307122

Genes

CETP
ADCY9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.PMID 28126828Read ↗

Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.Semantic proximity Read ↗

Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.Semantic proximity Read ↗

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.Semantic proximity Read ↗

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.Semantic proximity Read ↗

CETP inhibition and <i>ADCY9</i> genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease?Semantic proximity Read ↗

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.Semantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.Semantic proximity Read ↗

Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.Semantic proximity Read ↗

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.Semantic proximity Read ↗

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.